DOCSLIB.ORG

Evaluation of Possible Interaction Among Drugs Contemplated for Use During Manned Space Flights

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evaluation of Possible Interaction Among Drugs Contemplated for Use During Manned Space Flights EVALUATION OF POSSIBLE INTERACTION AMONG DRUGS CONTEMPLATED FOR USE DURING MANNED SPACE FLIGHTS Progress Report For The Period July 1972 To September 1973 prepared for MANNED SPACECRAFT CENTER NATIONAL AERONAUTICS AND SPACE ADMINISTRATION HOUSTON, TEXAS by ARTHUR D. LITTLE, INC. CAMBRIDGE, MASSACHUSETTS 02140 L CONTRACT NAS 9-12970 OCTOBER 31, 1973 3 l161) EVALUATION OF POSSIBLE NASA-CF=1 FOR INTERACTION AMONG DRUGS CONTEMPLATED USE DURING MNANE SPACE FLIGHTS Unclas Progress Report, Jul, (Little (Arthur 2378 Do), Inc,) 2-7-p HC CSCL ,60 G3/4 23 I/z Fni CES SUBJELT TW : EVALUATION OF POSSIBLE INTERACTION AMONG DRUGS CONTEMPLATED FOR USE DURING MANNED SPACE FLIGHTS PROGRESS REPORT FOR THE PERIOD JULY 1972 TO SEPTEMBER 1973 PREPARED FOR MANNED SPACECRAFT CENTER NATIONAL AERONAUTICS AND SPACE ADMINISTRATION HOUSTON, TEXAS CONTRACT NAS 9-12970 Arthur D Little, Inc. October 31, 1973 C-74804 I TABLE OF CONTENTS Page No. LIST OF TABLES v LIST OF FIGURES Vii FOREWORD 1 SUMMARY 3 I. INTRODUCTION 5 II. BACKGROUND 7 A. Studies of Potential Interactions between Nitrofurantoin and Chloral Hydrate, Barbiturate, or Flurazepam In Vitro and In Vivo 7 Nitrofurantoin 7 Chloral Hydrate 8 Barbiturate 8 Flurazepam 10 B. Studies of Potential Interactions of Enzyme Inducers with Phenazopyridine 14 Phenobarbital 16 Flurazepam 17 C. Study of the Effect of Diphenoxylate on the Bioavailability of Nitrofurantoin 17 Nitrofurantoin 19 III. RESULTS 25 A. Studies of Potential Interaction between Nitro- furantoin and Chloral Hydrate, Barbiturates, or Flurazepam In Vitro and In Vivo 25 1. Summary 25 2. Introduction 25 3. Materials and Methods 26 4. Results and Discussion (a) Microsomal Studies 33 (b) Pharmacological Studies 44 PRECEDING PAGE BLANK NOT FILMED iii Arthur D Little, Inc TABLE OF CONTENTS - CONTINUED B. Studies of Potential Interactions of Enzyme Inducers with Phenazopyridine 47 1. Summary 47 2. Introduction 47 3. Materials and Methods 48 4. Results and Discussion (a) Induction of Azoreductase 50 (b) Methemoglobin Production by Phenazo- pyridine 53 C. Studies on the Effects of Diphenoxylate on the Bioavailability of Nitrofurantoin 77 1. Summary 77 2. Introduction 78 3. Materials and Methods 79 4. Results and Discussion (a) Studies in Dogs 85 (b) Studies in Man 102 IV. REFERENCES 112 V. APPENDIX 117 VI. DISTRIBUTION LIST 120 iv Arthur D Little, Inc LIST OF TABLES No. Page No. 1 Effect of chronic treatment with nitrofurantoin 34 on total body and liver weight and yield of microsomal protein 2 Effect of chronic treatment with nitrofurantoin on 35 rat liver cytochrome 3 Microsomal hexobarbital oxidase activity after 36 chronic nitrofurantoin premedication 4 Metabolic rates of meperidine in vitro using liver 39 microsomes from control and nitrofurantoin-treated rats 5 Microsomal nitroreductase activity after chronic 42 nitrofurantoin premedication 6 Effect of chronic dosing with nitrofurantoin on 45 hexobarbital- and chloral hydrate-induced sleeping times in rats 7 Measurement of azoreductase induction in control 52 and phenobarbital-treated rats 8 Effect of phenobarbital pretreatment on liver weights 54 and protein levels of rats 9 Measurement of azoreductase induction in control and 55 flurazepam-treated rats 10 Effect of flurazepam treatment in rats on liver weights 56 and protein levels 11 Effect of chronic dosing with flurazepam on cytochrome 57 enzyme levels in rat liver microsomes 12 Levels of methemoglobin in control and phenobarbital- 61 treated rats following multiple doses of phenazopyridine 13 Levels of methemoglobin in control and phenobarbital- 63 treated rats following a single dose of phenazo- pyridine 14 Level of methemoglobin in control and phenobarbital- 65 .treated rats following multiple doses of phenazo- pyridine v Arthur D Little, Inc No. Page 15 Levels of methemoglobin in control and flurazepam- 71 treated rats following multiple doses of phenazo- pyridine 16 Levels of methemoglobin in control and flurazepam- 73 treated rats following a single dose of phenazopyridine 17 Levels of methemoglobin in control and flurazepam- 75 treated rats following multiple doses of phenazo- pyridine 18 The sequence of administering diphenoxylate and 84 nitrofurantoin in six human subjects 19 Cumulative percent of Macrodantin and Furadantin 102 excreted by dogs with/without diphenoxylate pretreatment 20 Cumulative percent of Macrodantin and Furandantin® 110 excreted by man with/without diphenoxylate pretreatment vi Arthur D Little, Inc LIST OF FIGURES No. Page 1 Metabolism of chloral hydrate 9 2 Proposed metabolism of flurazepam 11 3 Model for rate of appearance of unchanged drug in urine 21 4 Typical cumulative excretion of drug in urine 22 5 Difference spectra of cytochrome b 5 31 6 Difference spectra of cytochrome P-450 32 7 Lineweaver-Burk plot of hexobarbital oxidase activity 37 in control and nitrofurantoin-treated rats 8 Lineweaver-Burk plot of N-demethylase activity in 40 control and nitrofurantoin-treated rats 9 Rate of production of p-aminobenzoic acid from 41 p-nitrobenzoic acid at several substrate concentrations 10 Lineweaver-Burk plot of nitroreductase activity in 43 control and nitrofurantoin-treated rats 11 Standard curve for methemoglobin determination 51 12 Concentration of methemoglobin following a single 58 dose of aniline (500 mg/kg) in control and pheno- barbital-treated rats 13 Concentration of methemoglobin following a single dose 59 of aniline (1 g/kg) in control and phenobarbital- treated rats 14 Level of MHb found in the blood of a dog following 69 a single dose (200 mg/kg) of aniline 15 Standard curve of nitrofurantoin in urine 81 16 Cumulative excretion of Macrodantin in the urine 86 of all the dogs. 17 Cumulative excretion of Furadantin ®in the urine of 87 all the dogs 18 Cumulative excretion of Macrodantin and Furadantin® 88 in the urine of Dog 100 vii Arthur D Little, lnc LIST OF FIGURES - CONTINUED No. Page 19 Cumulative excretion of Macrodantin and Furadantin 89 in the urine of Dog 101 20 Cumulative excretion of Macrodantin and Furadantin 90 in the urine of Dog 102 21 Cumulative excretion of Macrodantin and Furadantin 92 in the urine of Dog 103 22 Cumulative excretion of Macrodantin in the urine 93 of Dog 100 with/without diphenoxylate 23 Cumulative excretion of Macrodantin in the urine 94 of Dog 101 with/without diphenoxylate 24 Cumulative excretion of Macrodantin in the urine 95 of Dog 102 with/without diphenoxylate 25 Cumulative excretion of Macrodantin in the urine 96 of Dog 103 with/without diphenoxylate 26 Cumulative excretion of Furadantin in the urine 97 of Dog 100 with/without diphenoxylate 27 Cumulative excretion of Furadantin in the urine 98 of Dog 101 with/without diphenoxylate 28 Cumulative excretion of Furadantin ©in the urine 99 of Dog 102 with/without diphenoxylate 29 Cumulative excretion of Furadantin in the urine 100 of Dog 103 with/without diphenoxylate 30 Cumulative excretion of Macrodantin and Furadantin® 104 with/without diphenoxylate in the urine of subject No. 1 31 Cumulative excretion of Macrodantin and Furadantin® 105 with/without diphenoxylate in the urine of subject No. 2 32 Cumulative excretion of Macrodantin and Furadantin 106 with/without diphenoxylate in the urine of subject No. 3 33 Cumulative excretion of Macrodantin® and Furadantin 107 with/without diphenoxylate in the urine of subject No. 4 34 Cumulative excretion of Macrodantin® and Furadantin® 108 with/without diphenoxylate in the urine of subject No. 5 35 Cumulative excretion of Macrodantin and Furadantin® 109 with/without diphenoxylate in the urine of subject No. 6 viii Arthur D Little, Inc FOREWORD This program was undertaken to evaluate possible interactions among drugs contemplated for use during manned space flights. It was carried out during the period July 1, 1972 to September 30, 1973 and was the subject of our proposals dated March 10, 1972 and May 14, 1973, in response to RFP No. 9-13B32-79-2-185P and RFP No. 9-13B631-4-3177P. The program will continue until June 30, 1974. Dr. Vernon Carter of the NASA Manned Spacecraft Center is Technical Officer for this agency. Dr. David W. Yesair, Dr. Francis J. Bullock (former Arthur D. Little, Inc. staff member), Dr. Philip S. Thayer, Mrs. Marianne Callahan, and Mr. James Braun comprise the Arthur D. Little, Inc., project team. 1 Arthur D Little, Inc SUMMARY Possible interactions among drugs contemplated for use during manned spaceflights have been studied in several animal species. The following seven drugs were investigated: nitrofurantoin, chloral hydrate, hexobarbital, phenobarbital, flurazepam, diphenoxylate, and phenazopyridine. Particular combinations included: chloral hydrate, hexobarbital or flurazepam with nitrofurantoin; phenobarbital or flurazepam with phenazo- pyridine; and diphenoxylate with two dose formulations of nitrofurantoin. Specifically, rat liver microsomes were used to determine whether chronic dosage with nitrofurantoin would inhibit rates of oxidative drug metabolism. Rates of hexobarbital oxidation, N-demethylation of meperidine, and reduction of p-nitrobenzoic acid were studied in control and nitro- furantoin-treated rats. No difference in oxidative metabolic rates were found between control and nitrofurantoin-treated rats. Pharmacological studies were carried out to determine whether premedication of rats with nitrofurantoin would result in potentiation of activity of hexobarbital, chloral hydrate, or flurazepam. This was determined for chloral hydrate and hexobarbital by studies of sleeping times determined by loss of the righting reflex. Flurazepam
Load more

Recommended publications
  • Determination of Barbiturates and 11-Nor-9-Carboxy-Δ9-THC in Urine
    Determination of Barbiturates and 11-Nor-9-carboxy- 9-THC in Urine using Automated Disposable Pipette Extraction (DPX) and LC/MS/MS Fred D. Foster, Oscar G. Cabrices, John R. Stuff, Edward A. Pfannkoch GERSTEL, Inc., 701 Digital Dr. Suite J, Linthicum, MD 21090, USA William E. Brewer Department of Chemistry and Biochemistry, University of South Carolina, 631 Sumter St. Columbia, SC 29208, USA KEYWORDS DPX, LC/MS/MS, Sample Preparation, High Throughput Lab Automation ABSTRACT This work demonstrates the use of disposable pipette extraction (DPX) as a fast and automated sample preparation technique for the determination of barbiturates and 11-nor-9- carboxy- 9-THC (COOH-THC) in urine. Using a GERSTEL MultiPurpose Sampler (MPS) with DPX option coupled to an Agilent 6460 LC-MS/MS instrument, 8 barbiturates and COOH-THC were extracted and their concentrations determined. The resulting average cycle time of 7 min/ sample, including just-in-time sample preparation, enabled high throughput screening. Validation results show that the automated DPX-LC/ AppNote 1/2013 MS/MS screening method provides adequate sensitivity for all analytes and corresponding internal standards that were monitored. Lower limits of quantitation (LLOQ) were found to be 100 ng/mL for the barbiturates and 10 ng/mL for COOH-THC and % CVs were below 10 % in most cases. INTRODUCTION The continuously growing quantity of pain management sample extract for injection [1-2]. The extraction of the drugs used has increased the demand from toxicology Barbiturates and COOH-THC is based on the DPX-RP- laboratories for more reliable solutions to monitor S extraction method described in an earlier Application compliance in connection with substance abuse and/or Note detailing monitoring of 49 Pain Management diversion.
    [Show full text]
  • Intravenous Anesthetics  a Drug That Induces Reversible Anesthesia  the State of Loss of Sensations, Or Awareness
    DR.MED. ABDELKARIM ALOWEIDI AL-ABBADI ASSOCIATE PROF. FACULTY OF MEDICINE THE UNIVERSITY OF JORDAN Goals of General Anesthesia Hypnosis (unconsciousness) Amnesia Analgesia Immobility/decreased muscle tone (relaxation of skeletal muscle) Reduction of certain autonomic reflexes (gag reflex, tachycardia, vasoconstriction) Intravenous Anesthetics A drug that induces reversible anesthesia The state of loss of sensations, or awareness. Either stimulates an inhibitory neuron, or inhibits an excitatory neuron. Organs are divided according to blood perfusion: High- perfusion organs (vessel-rich); brain takes up disproportionately large amount of drug compared to less perfused areas (muscles, fat, and vessel-poor groups). After IV injection, vessel-rich group takes most of the available drug Drugs bound to plasma proteins are unavailable for uptake by an organ After highly perfused organs are saturated during initial distribution, the greater mass of the less perfused organs continue to take up drug from the bloodstream. As plasma concentration falls, some drug leaves the highly perfused organs to maintain equilibrium. This redistribution from the vessel-rich group is responsible for termination of effect of many anesthetic drugs. Compartment Model Inhibitory channels : GABA-A channels ( the main inhibitory receptor). Glycine channels. Excitatory channels : Neuronal nicotic. NMDA. Rapid onset (mainly unionized at physiological pH) High lipid solubility Rapid recovery, no accumulation during prolonged infusion Analgesic
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Protecting Mental Health in the Age of Anxiety: the Context of Valium's Development, Synthesis, and Discovery in the United States, to 1963 Catherine (Cai) E
    Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2009 Protecting mental health in the Age of Anxiety: The context of Valium's development, synthesis, and discovery in the United States, to 1963 Catherine (cai) E. Guise-richardson Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the History Commons Recommended Citation Guise-richardson, Catherine (cai) E., "Protecting mental health in the Age of Anxiety: The onc text of Valium's development, synthesis, and discovery in the United States, to 1963" (2009). Graduate Theses and Dissertations. 10574. https://lib.dr.iastate.edu/etd/10574 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Protecting mental health in the Age of Anxiety: The context of Valium’s development, synthesis, and discovery in the United States, to 1963 by Catherine (Cai) Guise-Richardson A dissertation submitted to the graduate faculty in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Major: History of Technology and Science Program of Study Committee: Hamilton Cravens, Co-Major Professor Alan I Marcus, Co-Major Professor Amy Sue Bix Charles Dobbs David Wilson Iowa State University Ames, Iowa 2009 Copyright © Catherine (Cai) Guise-Richardson, 2009. All rights reserved. ii TABLE OF CONTENTS LIST OF TABLES iv ABSTRACT v CHAPTER 1.
    [Show full text]
  • A Fast Analytical LC/MS/MS Method for the Simultaneous Analysis of Barbiturates and 11-Nor-9-Carboxy-Δ9- Tetrahydrocannabinol (THC-A) in Urine
    Application Note Clinical Research A Fast Analytical LC/MS/MS Method for the Simultaneous Analysis of Barbiturates and 11-nor-9-carboxy-Δ9- tetrahydrocannabinol (THC-A) in Urine Using ESI negative ionization mode and alternating column regeneration Authors Abstract Andre Szczesniewski and Most of the compounds in large drug panels are analyzed using positive ionization Carrie J. Adler mode. However, barbiturates and 11-nor-9-carboxy-Δ9-THC (THC-A) perform better Agilent Technologies, Inc. using electrospray ionization (ESI) in negative mode with the mobile phase pH favorable for negative ionization. This work developed a fast analytical method combining eight barbiturates and THC-A in a single analysis using alternating column regeneration (ACR) to increase sample throughput. Moving the analytes preferring negative ionization into a separate test increases the analytical sensitivity of the compounds, allowing for greater research capabilities. The simple sample preparation techniques used provided rapid analysis, good analytical sensitivity, and quantitation over a wide dynamic range. This analysis used an Agilent 6470 triple quadrupole mass spectrometer with Agilent Jet Stream technology in ESI negative ionization mode and an Agilent Infinity II 1290 UHPLC system. A second pump and 2-position 10-port switching valve were added to facilitate use of the ACR. A 100 µL aliquot of human urine was used for the analysis of barbiturates and THC-A. Chromatographic separation of the analytes was achieved in less than 3 minutes using a gradient method composed of a H2O:acetonitrile mixture with 5 mM ammonium acetate and two Agilent Poroshell 120 EC-C18, 2.1 × 100 mm, 1.9 μm columns.
    [Show full text]
  • Pharmacological Review of Chemicals Used for the Capture of Animals
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Proceedings of the 7th Vertebrate Pest Vertebrate Pest Conference Proceedings Conference (1976) collection March 1976 PHARMACOLOGICAL REVIEW OF CHEMICALS USED FOR THE CAPTURE OF ANIMALS Peter J. Savarie U.S. Fish and Wildlife Service Follow this and additional works at: https://digitalcommons.unl.edu/vpc7 Part of the Environmental Health and Protection Commons Savarie, Peter J., "PHARMACOLOGICAL REVIEW OF CHEMICALS USED FOR THE CAPTURE OF ANIMALS" (1976). Proceedings of the 7th Vertebrate Pest Conference (1976). 41. https://digitalcommons.unl.edu/vpc7/41 This Article is brought to you for free and open access by the Vertebrate Pest Conference Proceedings collection at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Proceedings of the 7th Vertebrate Pest Conference (1976) by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. PHARMACOLOGICAL REVIEW OF CHEMICALS USED FOR THE CAPTURE OF ANIMALS* PETEIR J. SAVARIE, U.S. Fish and Wildlife Service, Building 16, Federal Center, Denver, Colorado 80225 ABSTRACT: A review of the literature reveals that over 60 chemicals have been used for the capture of wi l d animals, but only 30 of the most widely used chemicals are discussed in the present paper. For practical considerations these chemicals can be c l a ssified as being either (l) neuromuscular blocking agents, or (2) central nervous system (CNS) depressants. Some common neuromuscular blocking agents are d-tubocurarine, gallamine, succiny1choline, and nicotine. M99 and its derivatives, phencyclidine, and xylazine are some of the more commonly used CNS depressants. Neuromuscular blocking agents have a relatively rapid onset and short duration of action but they do not possess sedative, analgesic, or anesthetic properties.
    [Show full text]
  • Capítulo 30 Anestesia Intravenosa
    Capítulo 30 Anestesia intravenosa JAAP VUYK • ELSKE SITSEN • MARIJE REEKERS Agradecimientos. Los redactores y el editor desean agradecer a los Dres. J. G. Reves, Peter Glass, David A. Lubarsky, Matthew D. McEvoy y Ricardo Martinez-Ruiz la aportación de un capítulo sobre el mismo tema en la edición previa de este tratado, que ha servido de base para el presente capítulo. P UNTOS CLAVE • La introducción de tiopental en la práctica clínica en 1934 supuso el comienzo de la era de la anestesia intravenosa (i.v.) moderna. Hoy en día, los anestésicos i.v. forman parte de la inducción y el mantenimiento de la anestesia y la sedación en un amplio abanico de situaciones. • El anestésico i.v. más utilizado es el propofol, un alquilfenol formulado en emulsión lipídica. Se trata de un fármaco que ofrece rapidez de inicio y finalización de acción, así como tiempos decrecientes concordantes con el contexto de unos 10 min en infusiones de duración menor de 3 h e inferior a 40 min en aquellas de hasta 8 h. Su mecanismo de acción podría corresponder a la potenciación de las corrientes de cloro inducidas por el ácido g-aminobutírico (GABA). El propofol induce una disminución dependiente de la dosis de la presión arterial media por sendas reducciones del gasto cardíaco y la resistencia vascular periférica, y ocasiona una depresión respiratoria moderada. El efecto antiemético constituye un rasgo exclusivo de este compuesto incluso a concentraciones menores de las que producen sedación. • Los barbitúricos constituían los fármacos i.v. más utilizados en la inducción de la anestesia con anterioridad a la introducción del propofol.
    [Show full text]
  • 6. TOXICOKINETICS and METABOLISM 6.1 Introduction
    6. TOXICOKINETICS AND METABOLISM 6.1 Introduction The binding of carbon monoxide to haemoglobin, producing car- boxyhaemoglobin, decreases the oxygen carrying capacity of blood and interferes with oxygen release at the tissue level; these two main mechanisms of action underlie the potentially toxic effects of low- level carbon monoxide exposure. Impaired delivery of oxygen can interfere with cellular respiration and result in tissue hypoxia. Hypoxia of sensitive tissues, in turn, can affect the function of many organs, including the lungs. The effects would be expected to be more pronounced under conditions of stress, as with exercise, for example. Although the principal cause of carbon monoxide-induced toxicity at low exposure levels is thought to be increased carboxyhaemoglobin formation, the physiological response to carbon monoxide at the cellu- lar level and its related biochemical effects are still not fully under- stood. Other mechanisms of carbon monoxide-induced toxicity have been hypothesized and assessed, such as hydroxyl radical production (Piantadosi et al., 1997) and lipid peroxidation (Thom, 1990, 1992, 1993) in the brain of carbon monoxide-poisoned rats, but none has been demonstrated to operate at relatively low (near-ambient) carbon monoxide exposure levels. 6.2 Endogenous carbon monoxide production In addition to exogenous sources, humans are also exposed to small amounts of carbon monoxide produced endogenously. In the process of natural degradation of haemoglobin to bile pigments, in concert with the microsomal reduced nicotinamide adenine dinucleo- tide phosphate (NADPH) cytochrome P-450 reductase, two haem oxygenase isoenzymes, HO-1 and HO-2, catalyse the oxidative break- down of the "-methene bridge of the tetrapyrrol ring of haem, leading to the formation of biliverdin and carbon monoxide.
    [Show full text]
  • Interaction of Cannabis and General Anaesthetic Agents in Mice G.B
    Br. J. Pharmac. (1974), 50, 593-599 INTERACTION OF CANNABIS AND GENERAL ANAESTHETIC AGENTS IN MICE G.B. CHESHER, D.M. JACKSON & G.A. STARMER Department of Pharmacology, University of Sydney, Sydney 2006, Australia 1 A cannabis extract (I) (in a concentration equivalent to 10 mg A9-tetrahydro- cannabinol(THC)/kg) prolonged pentobarbitone anaesthesia in mice maximally 20 min to 2 h after medication. The effect was still significant after 8 h, but less than at 2 hours. 2 The cannabis extract (1) (equivalent to 10 mg A9-THC/kg) prolonged both pentobarbitone and ether anaesthesia in mice when administered 20 min before the anaesthetic. After eight consecutive daily doses of cannabis, the pentobarbitone anaesthesia was still significantly longer than a control group, while ether anaesthesia was not significantly prolonged. 3 A second cannabis extract (II) with a different ratio of cannabinoids (also administered in dosage equivalent to 10 mg A9-THC/kg) failed to affect pentobarbitone anaesthesia in mice. This extract presented about 4% the dose of cannabidiol as extract I. 4 A8-THC, A9-THC and cannabidiol prolonged pentobarbitone anaesthesia with cannabidiol being generally more active than A 9 -THC. Cannabinol ( 10 mg/kg) was inactive. 5 The effects of cannabidiol and A9-THC were found to be additive, and there was a consistent trend for cannabinol to reduce the effectiveness of A9-THC and cannabidiol when given in combination. 6 Premedication with phenoxybenzamine, phentolamine, propranolol, iproniazid, protripty- line, desipramine, reserpine, ai-methyl tyrosine or parachlorophenylalanine did not affect the extract I-induced prolongation of pentobarbitone anaesthesia. 7 It is concluded that cannabis may affect pentobarbitone and ether anaesthesia in mice at least partially by a direct depressant effect, and that the cannabis-induced prolongation of anaesthesia is probably unrelated to any effect on central 5-hydroxytryptamine or catechol- amine neurones.
    [Show full text]
  • Genetic Control of the Phenobarbital-Induced Shortening of Plasma Antipynrne Half-Lives in Man
    Genetic Control of the Phenobarbital-Induced Shortening of Plasma Antipynrne Half-Lives in Man ELLIoT S.; VESELL and JoHN G. PAGE From the Section on Pharmacogenetics, Laboratory of Chemical Pharmacology, National Heart Institute, National Institutes of Health, Bethesda, Maryland 20014 A B S T R A C T The mean half-life of antipyrine in the twins indicate genetic, rather than environmental, con- plasma of four sets of identical and four sets of fraternal trol of phenobarbital-induced alterations in plasma anti- twins after a single oral dose of 16 mg/kg of antipyrine pyrine half-life. was 12.7 ±SD 3.3 hr. After 2 wk on sodium pheno- barbital (2 mg/kg daily) the half-life of antipyrine in the plasma of these twins was reduced to 8.0 ±SD 1.5 hr. INTRODUCTION Shortening of the plasma antipyrine half-life occurred in Genetic control of induction in man. By changing all but one of these 16 normal, adult volunteers, but rates of drug metabolism in hepatic microsomes, numer- there was considerable variation in the extent of reduc- ous factors may substantially modify the duration and tion which ranged from 0 to 69%. Phenobarbital admin- intensity of action of various therapeutic agents. Al- istration decreased individual variations in antipyrine though genetic, dietary, hormonal, and nutritional causes metabolism as indicated by the smaller standard deviation of alterations in the drug-metabolizing activities of of the plasma antipyrine half-lives after phenobarbital hepatic microsomes have been investigated, particular than observed initially and by the narrowed range of attention has focused on certain foreign compounds that variation in plasma antipyrine half-lives from 2.8-fold augment these activities (1-11).
    [Show full text]
  • Sex and Age Differences in the Effects of Barbiturates
    SEX AND AGE DIFFERENCES IN THE EFFECTS OF BARBITURATES TOMOKO FUJII, MICHIKO IMAI, CHIKA MOROHASHI, MIKO WAKAHARA, MASAKO WATANABEE AND RYOSHU KOYAMA Departmentof Pharmacology,Tokyo Women's Medical College, Shinjuku-ku, Tokyo Receivedfor publication October 26, 1964 It was reported that there was a remarkable difference in the effects of pentobar bital (1) or hexobarbital (2) between adult female and male rats and that there was a sex difference in the metabolism of these drugs (1, 2). However, most works on the effects of barbiturates had been done with either male or female animals only. More over, the reports on the sex difference of the effects of barbiturates were principally concerned with the single injection of drug. The authors have reported that the sex difference was observed in the effects of some hormones on the growth and development of rats and the enzyme activity in the rat's liver (3-5). The purpose of the present -study was to compare the effects in male and female rats of continued daily injection of pentobarbital as well as phenobarbital. The develop ment of the tolerance to drugs and the existence of sex difference in drug effects were observed. MATERIALSAND METHODS Adult (about 3 months of age) and immature rats (about 3 weeks of age) of Wistar King A strain were used. Rats were bred in this department and took the compressed diet (Oriental Co.) and water ad libitum. All rats were kept at a temperature of 23 -F2°C and 55±5% in humidity . Pentobarbital sodium in aqueous solution was injected subcutaneously or intra peritoneally in doses of 30 and 40 mg/kg.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]